19th October 2018

Creo Medical secures European distribution agreements

Chepstow-headquartered surgical device company Creo Medical has secured framework distribution agreements for four EU countries.

The company, which produces devices for the emerging field of surgical endoscopy, has entered into the agreements to provide clinical training and market seeding across the Spanish, Belgian, Dutch and Luxembourg markets for Creo’s CROMA and Speedboat products, ahead of their full commercial launch in 2019.

Creo has signed an agreement with Spanish distributor, JJP Hospitalaria SL covering the Spanish market and an agreement with Netherlands based distributor STINNOW medical to cover Belgium, the Netherlands and Luxembourg (Benelux).

Both distributors will collaborate with Creo over an 18-month period to advance the roll out of Creo’s clinical education programme across Spain and Benelux educating key clinicians in the use of Speedboat and the CROMA platform with the aim of ensuring quality control and best patient outcomes.

Craig Gulliford, chief executive, said: “Entering mainland Europe is an important milestone for Creo as we work towards commercialisation of our lead product, Speedboat, powered by our CROMA advanced energy platform.

“This will be the first time Creo has shipped products to these areas which we believe will be key markets for the company. The signing of these agreements is in line with our strategy to grow our distribution network and reputation both in Europe and worldwide and will position us well as we strive to advance the emerging field of surgical endoscopy.”

The agreement follows a visit from Welsh Government cabinet secretary for health and social services Vaughan Gething.

Gulliford continued: “Developing innovative medical technologies is at the heart of the Welsh Government’s vision for the future of the NHS in Wales.  We welcome the Welsh Government’s continued support of medtech innovation as we roll-out our extensive training led commercialisation strategy and transform the field of minimal invasive surgery globally.”

View Creo’s profile here.